• Profile
Close

Effect of human recombinant alkaline phosphatase on 7-day creatinine clearance in patients with sepsis-associated acute kidney injury: A randomized clinical trial

JAMA Oct 28, 2018

Pickkers P, et al. - Among critically ill patients with sepsis-associated acute kidney injury, researchers tested the efficacy of human recombinant alkaline phosphatase in improving kidney function. No remarkable improvement was evident in short-term kidney function in these patients with human recombinant alkaline phosphatase vs placebo.

Methods

  • Including 301 adult patients admitted to the intensive care unit with a diagnosis of sepsis and AKI, an international (53 recruiting sites), randomized, double-blind, placebo-controlled, dose-finding, adaptive phase 2a/2b study (STOP-AKI trial) was performed.
  • Enrollment of patients was carried out between December 2014 and May 2017, and patients were followed-up for 90 days; the final date of follow-up was August 14, 2017.
  • To establish the optimal dose, recombinant alkaline phosphatase in a dosage of 0.4 mg/kg (n=31), 0.8 mg/kg (n=32), or 1.6 mg/kg (n=29) or placebo (n=30) was administered randomly to patients, once daily for 3 days, in the intention-to-treat analysis in part 1 of the trial.
  • On the basis of modeling approaches and adverse events, 1.6 mg/kg was identified as the optimal dose.
  • Comparison of 1.6 mg/kg (n=82) to placebo (n=86) was done in part 2.
  • Time-corrected area under the curve of the endogenous creatinine clearance for days 1 through 7, divided by 7 to provide a mean daily creatinine clearance (AUC1-7ECC), was considered as the primary end point.
  • Also, evaluation of incidence of fatal and nonfatal (serious) adverse events ([S]AEs) was carried out.

Results

  • A total of 301 patients were enrolled (men, 70.7%; median age, 67 years [interquartile range {IQR}, 59-73]).
  • In the recombinant alkaline phosphatase vs in the placebo group, the observed median ECC increase from day 1 to day 7 was from 26.0 mL/min (IQR, 8.8 to 59.5) to 65.4 mL/min (IQR, 26.7 to 115.4) vs from 35.9 mL/min (IQR, 12.2 to 82.9) to 61.9 mL/min (IQR, 22.7 to 115.2), respectively (absolute difference, 9.5 mL/min [95% CI, −23.9 to 25.5]; P=.47).
  • The occurrence of fatal adverse events was reported in 26.3%, 17.1%, 17.4%, and 29.5% patients in the 0.4-mg/kg recombinant alkaline phosphatase group, 0.8-mg/kg group, 1.6-mg/kg group, and in the placebo group, respectively.
  • For the 0.4-mg/kg recombinant alkaline phosphatase group, 0.8-mg/kg group, 1.6-mg/kg group, and for the placebo group, the observed rates of nonfatal SAEs were 21.0%, 14.3%, 25.7%, and 20.5%, respectively.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay